- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02010502
Beet Root Supplement Trial
January 29, 2020 updated by: University of Manitoba
Effects of Two Forms of Beetroot Juice Supplementation on Exercise Performance in Cyclists
To examine the effects of two forms of beetroot juice supplementation on exercise performance in trained cyclists.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3T 6C5
- Richardson Centre for Functional Foods and Nutraceuticals
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- good physical health
- trained or competitive cyclist
- between 18-40 years of age
Exclusion Criteria:
- have used any anabolic or ergogenic supplementation in the last 1-3 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Concentrated Beet Root Juice
500ml per day for 6 days
|
|
|
ACTIVE_COMPARATOR: Beet root powder
500ml per day for 6 days
|
|
|
PLACEBO_COMPARATOR: Placebo juice
Negligible nitrate
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Time to completion
Time Frame: Baseline to week 8
|
Baseline to week 8
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
O2 consumption
Time Frame: Baseline to Week 8
|
Baseline to Week 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2013
Primary Completion (ACTUAL)
December 1, 2013
Study Completion (ACTUAL)
December 1, 2018
Study Registration Dates
First Submitted
December 9, 2013
First Submitted That Met QC Criteria
December 9, 2013
First Posted (ESTIMATE)
December 12, 2013
Study Record Updates
Last Update Posted (ACTUAL)
January 30, 2020
Last Update Submitted That Met QC Criteria
January 29, 2020
Last Verified
April 1, 2018
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- J2013:089
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Trained or Competitive Cyclists
-
Indiana UniversityNational Institute on Drug Abuse (NIDA)Enrolling by invitationCarrying Naloxone/Narcan on Their Person or in Their Vehicle | Being Trained to Respond to an Opioid OverdoseUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AkesoNot yet recruitingAtopic DermatitisChina
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States